Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Deloitte
Fuji
US Department of Justice
Baxter
Federal Trade Commission
Argus Health
QuintilesIMS
AstraZeneca

Generated: September 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,597,409

« Back to Dashboard

Which drugs does patent 9,597,409 protect, and when does it expire?

Patent 9,597,409 protects ABRAXANE and is included in one NDA.

This patent has thirty-four patent family members in twenty-two countries.

Summary for Patent: 9,597,409
Title:Methods of treating cancer
Abstract: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:13/782,990
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 9,597,409

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF LUNG CANCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,597,409

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011235344 ➤ Sign Up
Australia 2016202000 ➤ Sign Up
Brazil 112012024442 ➤ Sign Up
Canada 2793974 ➤ Sign Up
China 103118665 ➤ Sign Up
Costa Rica 20120528 ➤ Sign Up
Cyprus 1118216 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Dow
Boehringer Ingelheim
Cantor Fitzgerald
Express Scripts
Argus Health
Chubb
Queensland Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.